Health · Breaking
Democratic Republic of Congo, was administered to a volunteer in England for the first time in the world
- Scientists at Oxford University in England developed a new vaccine in a short period of eight weeks to combat the deadly Ebola epidemic in Africa.
- The experimental vaccine, produced using the vaccine technology used in the COVID-19 pandemic, was administered to a 37-year-old British volunteer named Ed Hunt for the first time in the world within the scope of clinical studies.
- In the first phase studies to be conducted on a total of 50 healthy people, the safety of the vaccine and the immune response it will create in the body are examined.
- This study, which targets the Bundibugyo strain, for which current Ebola vaccines are ineffective, is the first project to enter the human trial phase against this type of virus.
The new generation vaccine developed against the Ebola epidemic, which killed hundreds of people in the Democratic Republic of Congo, was administered to a volunteer in England for the first time in the world. Scientists at Oxford University in England developed a new vaccine in a short period of eight weeks to combat the deadly Ebola epidemic in Africa. The experimental vaccine, produced using the vaccine technology used in the COVID-19 pandemic, was administered to a 37-year-old British volunteer named Ed Hunt for the first time in the world within the scope of clinical studies.
In the first phase studies to be conducted on a total of 50 healthy people, the safety of the vaccine and the immune response it will create in the body are examined. This study, which targets the Bundibugyo strain, for which current Ebola vaccines are ineffective, is the first project to enter the human trial phase against this type of virus. Experts emphasize that the experimental vaccine does not contain viruses and poses absolutely no risk of disease to participants.
The Oxford team plans to move on to larger field tests in Uganda and the Democratic Republic of Congo once the safety of the vaccine is proven. While more than 2,500 cases have been recorded in the epidemic region to date, the number of deaths has exceeded a thousand. Not wanting to waste time in the face of the magnitude of the threat, the Serum Institute of India keeps 600 thousand doses of this vaccine, which is still in the trial phase, on standby.
Source: TRT Haber